Tumor necrosis factor receptor 1 gain‐of‐function mutation aggravates nonalcoholic fatty liver disease but does not cause insulin resistance in a murine model*

Marcela Aparicio‐Vergara, Pascal P.H. Hommelberg, Marijke Schreurs, Nanda Gruben, Rinke Stienstra, Ronit Shiri‐Sverdlov, Niels J. Kloosterhuis, Alain de Bruin, Bart van de Sluis, Debby P.Y. Koonen, Marten H. Hofker – 3 September 2012 – Ectodomain shedding of tumor necrosis factor receptor 1 (TNFR1) provides negative feedback to the inflammatory loop induced by TNFα.

Telaprevir‐based triple therapy in liver transplant patients with hepatitis C virus: A 12‐week pilot study providing safety and efficacy data

Christoph R. Werner, Daniel P. Egetemeyr, Ulrich M. Lauer, Silvio Nadalin, Alfred Königsrainer, Nisar P. Malek, Christoph P. Berg – 1 September 2012 – After liver transplantation (LT), the management of recurrent hepatitis C virus (HCV) infections still remains a major challenge. In HCV genotype 1 patients not undergoing transplantation, the introduction of protease inhibitor (PI)–based regimens has increased the sustained virological response rate significantly.

Interferon‐gamma–mediated tissue factor expression contributes to T‐cell‐mediated hepatitis through induction of hypercoagulation in mice

Junko Kato, Tomohiro Okamoto, Hiroyuki Motoyama, Ryosuke Uchiyama, Daniel Kirchhofer, Nico Van Rooijen, Hirayuki Enomoto, Shuhei Nishiguchi, Norifumi Kawada, Jiro Fujimoto, Hiroko Tsutsui – 30 August 2012 – Concanavalin A (Con A) treatment induces severe hepatitis in mice in a manner dependent on T cells, interferon (IFN)‐gamma, and tumor necrosis factor (TNF). Treatment with the anticoagulant heparin protects against hepatitis, despite healthy production of IFN‐γ and TNF. Here, we investigated molecular and cellular mechanisms for hypercoagulation‐mediated hepatitis.

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

Sudeep Tanwar, Paul M. Trembling, Indra N. Guha, Julie Parkes, Philip Kaye, Alastair D. Burt, Stephen D. Ryder, Guruprasad P. Aithal, Christopher P. Day, William M. Rosenberg – 29 August 2012 – Liver biopsy is the reference standard for the detection of nonalcoholic steatohepatitis (NASH) within nonalcoholic fatty liver disease (NAFLD). The aim of this study was to identify a biomarker of NASH in patients without significant fibrosis. In all, 172 patients from two centers with biopsy‐proven NAFLD were included in this study.

Subscribe to